Fluzoparib

Drug Profile

Fluzoparib

Alternative Names: SHR 3162

Latest Information Update: 14 Mar 2017

Price : $50

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Antineoplastics
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gastric cancer; Solid tumours

Most Recent Events

  • 14 Mar 2017 Jiangsu HengRui Medicine and Beijing Cancer Hospital plan a phase I trial for Ovarian cancer and Breast cancer (Combination therapy) in China (NCT03075462)
  • 18 Jan 2017 Jiangsu HengRui Medicine plans a phase I trial for Gastric cancer (Combination therapy, Recurrent, Metastatic disease, Second-line therapy or greater) in China (PO) (NCT03026881)
  • 04 Jan 2017 Jiangsu HengRui Medicine completes a phase I trial in Solid tumours (In volunteers) in China (NCT03062982)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top